Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes

Post time 2023-3-19 12:12:58

Edited by biosciencenow at 2023-3-19 14:02

journal：European Journal of Endocrinology

Authors：Soren S Lund; Lise Tarnow; Merete Frandsen; Ulla M Smidt; Oluf Pedersen; Hans-Henrik Parving; Allan A Vaag

Published date：2008-1-

DOI：10.1530/eje-07-0500

Article link：http://dx.doi.org/10.1530/eje-07-0500

Article Source：Oxford University Press (OUP)。

Remark：

Post time 2023-3-19 12:12:59

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes